CCL28 and influenza: Furthermore, studies have shown that the addition of a CCL28 adjuvant in H3N2 influenza vaccines can induce a significant increase in IgA levels and hemagglutination inhibition (HI) titers, enhancing long-term cross-protection against H3N2 influenza virus (85).